Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
Gelteq Limited (NASDAQ:GELS), a gel-based oral delivery solutions developer, announced the successful launch of its technology-enabled products in the U.S. market through its partnership with Healthy Extracts (OTCQB:HYEX).
This milestone marks Gelteq's transition from R&D to active commercialization in the U.S., with products now reaching their U.S. warehousing facility. The partnership, which began with warehousing and fulfillment arrangements, has progressed to active sales and distribution, demonstrating the potential of Gelteq's proprietary gel technology in the nutraceutical market.
Gelteq Limited (NASDAQ:GELS), azienda specializzata in soluzioni di somministrazione orale a base di gel, ha annunciato il riuscito lancio dei propri prodotti abilitati dalla tecnologia nel mercato statunitense attraverso la partnership con Healthy Extracts (OTCQB:HYEX).
Questo traguardo segna la transizione di Gelteq dalla Ricerca e Sviluppo alla commercializzazione attiva negli Stati Uniti, con i prodotti ora disponibili presso la loro installazione di magazzinaggio negli USA. La partnership, nata per accordi di stoccaggio e fulfillment, è progredita verso vendite e distribuzione attive, dimostrando il potenziale della tecnologia Gel proprietaria di Gelteq nel mercato nutraceutico.
Gelteq Limited (NASDAQ:GELS), empresa de soluciones de administración oral a base de gel, anunció el exitoso lanzamiento de sus productos habilitados por la tecnología en el mercado estadounidense a través de su asociación con Healthy Extracts (OTCQB:HYEX).
Este hito marca la transición de Gelteq de I+D a la comercialización activa en EE. UU., con los productos ya llegando a su instalación de almacenamiento en EE. UU. La asociación, que comenzó con acuerdos de almacenamiento y fulfillment, ha avanzado hacia ventas y distribución activas, demostrando el potencial de la tecnología de gel propietaria de Gelteq en el mercado nutracéutico.
Gelteq Limited (NASDAQ:GELS), 젤 기반 구강 전달 솔루션 개발 기업은 Healthy Extracts (OTCQB:HYEX)와의 파트너십을 통해 미국 시장에서 기술 기반 제품의 성공적인 출시를 발표했습니다.
이 이정표는 Gelteq가 연구 개발에서 미국 내 적극적 상용화로 전환되었음을 의미하며, 현재 미국 창고 시설에 제품이 도착했습니다. 창고 및 물류를 시작으로 한 파트너십은 적극적 판매 및 유통으로 발전했고, Gelteq의 독점 젤 기술이 뉴트러슈얼 시장에서의 잠재력을 보여주고 있습니다.
Gelteq Limited (NASDAQ:GELS), société spécialisée dans les solutions d'administration orale à base de gel, a annoncé le lancement réussi de ses produits propulsés par la technologie sur le marché américain grâce à son partenariat avec Healthy Extracts (OTCQB:HYEX).
Cette étape marque la transition de Gelteq de la R&D à la commercialisation active aux États-Unis, avec des produits qui atteignent désormais l’installation de stockage américaine. Le partenariat, qui avait commencé par des accords de stockage et de fulfilment, a évolué vers des ventes et une distribution actives, démontrant le potentiel de la technologie de gel propriétaire de Gelteq sur le marché des nutraceutiques.
Gelteq Limited (NASDAQ:GELS), ein Entwickler gelbasierter oraler Abgabesysteme, kündigte den erfolgreichen Markteintritt seiner technologiebasierten Produkte in den USA durch die Partnerschaft mit Healthy Extracts (OTCQB:HYEX) an.
Dieser Meilenstein markiert den Übergang von Gelteq von F&E zur aktiven Kommerzialisierung in den USA, wobei die Produkte nun ihre US-Lagerstätte erreichen. Die Partnerschaft, die mit Lagerung und Fulfillment begann, hat sich zu aktivem Verkauf und Vertrieb entwickelt und demonstriert das Potenzial der eigenen Gel-Technologie von Gelteq im nutraceutical-Markt.
Gelteq Limited (NASDAQ:GELS)، شركة مطوّرة لحلول التوصيل الفموية المعتمدة على الجل، أعلنت عن الإطلاق الناجح لمنتجاتها المدعومة بالتقنية في السوق الأمريكية من خلال شراكتها مع Healthy Extracts (OTCQB:HYEX).
هذا الإنجاز يمثل انتقال Gelteq من البحث والتطوير إلى التسويق النشط في الولايات المتحدة، حيث وصلت المنتجات الآن إلى منشأة التخزين الأمريكية. بدأت الشراكة بترتيبات التخزين والتنفيذ، لكنها تطورت إلى مبيعات وتوزيع نشطة، مما يبيّن إمكانات تكنولوجيا الجل المملوكة لـ Gelteq في سوق المستحضرات المغذية الصحية.
Gelteq Limited (NASDAQ:GELS)，是一家基于凝胶的口服递送解决方案开发商，宣布通过与 Healthy Extracts (OTCQB:HYEX) 的合作，在美国市场成功推出其以技术为支撑的产品。这一里程碑标志着 Gelteq 从研发向在美积极商业化的转变，产品现已抵达其在美国的仓储设施。该伙伴关系最初以仓储与履约安排为起点，现已发展为积极的销售与分销，展示了 Gelteq 的专有凝胶技术在保健营养品市场的潜力。
- First successful commercial product launch in the U.S. market
- Transition from R&D phase to active commercialization
- Established operational infrastructure with U.S. warehousing facility
- Partnership expansion from warehousing to active sales and distribution
- None.
MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently announced product launches of Healthy Extracts, Inc. (“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq’s proprietary gel technology, into the U.S. nutraceutical market.
The Healthy Extracts products are the first to reach Gelteq’s U.S. warehousing facility using Gelteq’s delivery platform, an important milestone that marks Gelteq’s transition from R&D to active commercialization in the U.S. This development highlights both the growth potential of Gelteq’s technology in large-scale wellness markets in the U.S. and its ability to meet consumer demand for innovative, convenient, and clinically-informed formats.
“We are pleased to see Gelteq’s technology expand into the U.S. market through our collaboration with Healthy Extracts,” said Nathan Givoni, CEO of Gelteq. “Healthy Extract’s launch demonstrates how our gels can be adapted to create differentiated, consumer-friendly solutions, while paving the way for additional products and partnerships across the U.S. market.”
The collaboration with Healthy Extracts, first announced earlier this year, began with warehousing and fulfilment arrangements which laid the foundation for Gelteq's entry into the U.S. market. With this launch, the partnership with Healthy Extract has advanced into active sales and distribution, underscoring the growing momentum behind Gelteq’s gel delivery system and the potential for additional partnership opportunities in the U.S.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit www.gelteq.com.
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
FAQ
What products did Gelteq (NASDAQ:GELS) launch in the U.S. market?
How is Gelteq (NASDAQ:GELS) entering the U.S. market?
What is the significance of Gelteq's (NASDAQ:GELS) U.S. product launch in September 2025?
Who is Gelteq's (NASDAQ:GELS) first U.S. commercial partner?
What is Gelteq's (NASDAQ:GELS) business model in the U.S. market?
